# Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)

> **NCT03775096** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Michele Tagliati, MD** · enrollment: 15 (estimated)

## Conditions studied

- REM Sleep Behavior Disorder
- Pre-motor Parkinson Disease
- Symptomatic Parkinson Disease

## Interventions

- **DRUG:** Carvedilol

## Key facts

- **NCT ID:** NCT03775096
- **Lead sponsor:** Michele Tagliati, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-04-04
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03775096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03775096, "Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03775096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*